SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

Lenard A. Adler, MD

Speaker Affiliation
Lenard A. Adler, MD
Director, Adult ADHD Program
Professor of Psychiatry and Child and Adolescent Psychiatry
NYU School of Medicine

: Pharmacotherapy of Adult ADHD and Co-Morbid Conditions
Activity/Course #:
: NCMEDP103x

: Free
Release/Start Date:
: Jan 02 2014
Expiration Date:
: Dec 31 2017
: Psychiatry
Target Audience:
: Primary Care Providers
: ADHD Dissemination Webcast
Estimated Time To Complete CME Activity:
: 0.5 Hours
: 0
Hardware/Software Requirements:
Welcome to Pharmacotherapy of Adult ADHD and Comorbid Conditions: A Guide for Primary Care Providers.

In this 32 minute webcast Dr. Lenard Adler reviews the FDA approved medications for adults with ADHD and provides an overview of research on safety and efficacy of medication options. This webcast is where you should to start to become familiar with medication treatment options.

Learning Objectives
After completing this module participants will be able to:

  1. Discuss pathophysiology of ADHD
  2. Discuss safety and efficacy of treating adults with ADHD with stimulant and non-stimulant medications
  3. Identify options for pharmcotherapy in adults with simple ADHD and ADHD plus comorbid psychiatric disorders

This webcast was recorded live and is being used with the permission of the presenter.

How To Obtain Your CME Certificate
Register for the course at
  1. View the content.
  2. Complete and submit the post-test and evaluation.
  3. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  4. Print your CME certificate.

Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure is provided below.

Lenard A. Adler, MD, Speaker, has the following relationships to disclose: Grant/Research Support: Bristol-Myers-Squibb, Pfizer, Shire, Eli Lilly, Ortho McNeil/Jannsen/Johnson and Johnson, National Institute of Drug Abuse; Advisory Board and Consultant: Eli Lilly, Major League Baseball, Mindsite, Organon, Ortho McNeil/Jannsen/Johnson and Johnson, Shire, i3 Research, Epi-Q, INC Research, AstraZeneca Pharmaceuticals; Consultant: Otsuka Pharmaceuticals

Harvey C. Parker, Ph.D., Activity Planning Committee, has the following relationships to disclose: co-owner of Specialty Press, Inc. and Health Link Systems, Inc.

Gregg Sherman, MD, Course Director, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This activity was originally supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding, visit

Continued support was provided by independent medical educational grant from Shire; and an educational grant from Arbor Pharmaceuticals.